Grifols Doses First Patients in Two Phase 3 Trials for Immunoglobulin Label Expansion
GRFS is trading near its 52-week low of $6.96 (1.0% above the low).
Summary
Grifols has dosed the first patients in two Phase 3 trials aiming to expand U.S. labels for its key immunoglobulin products, GAMUNEX-C and XEMBIFY. The SIGMA trial targets secondary immunodeficiency in blood cancer patients, a market of over 1 million U.S. patients, while XPERT tests XEMBIFY against GAMUNEX-C in CIDP, a 60,000-patient indication. These trials build on the strong commercial momentum of the Ig portfolio, with XEMBIFY growing nearly 60% in 2025. Positive results could unlock significant new revenue streams and reinforce the company's turnaround narrative following recent debt refinancing and credit upgrades. The stock trades near its 52-week low, so pipeline progress may draw attention to undervalued growth prospects.
At the time of this announcement, GRFS was trading at $7.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $6.96 to $11.14. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.